CLOTRIMAZOLE

US Approved OTC

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H17ClN2
Molecular Weight	344.837
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=C(C=CC=C1)C(N2C=CN=C2)(C3=CC=CC=C3)C4=CC=CC=C4

InChI

InChIKey=VNFPBHJOKIVQEB-UHFFFAOYSA-N

InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H

HIDE SMILES / InChI

Molecular Formula	C22H17ClN2
Molecular Weight	344.837
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018052Orig1s032lbl.pdf

Clotrimazole is an anti-fungal medicine indicated for the treatment of vaginal yeast infections and tinea. It can be used either in combination with other drugs (betamethasone dipropionate) or alone, in form of topical or vaginal cream. The drug exerts its action by inhibiting lanosterol demethylase thereby affecting the growth of fungi.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytochrome P450 51 28 Target ID: CHEMBL1780 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf	Inhibitor 8297		19.7 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Vaginal yeast infections 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018052Orig1s032lbl.pdf	Curative	Approved 8429	GYNE-LOTRIMIN Approved Use To treat vaginal yeast infections. Launch Date 1.96473602E11
Tinea pedis 28 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf	Curative	Approved 8429	LOTRISONE Approved Use LOTRISONE cream contains a combination of clotrimazole, an azole antifungal, and betamethasone dipropionate, a corticosteroid, and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. Launch Date 4.58265592E11
Tinea cruris 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf	Curative	Approved 8429	LOTRISONE Approved Use LOTRISONE cream contains a combination of clotrimazole, an azole antifungal, and betamethasone dipropionate, a corticosteroid, and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. Launch Date 4.58265592E11
Tinea corporis 19 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf	Curative	Approved 8429	LOTRISONE Approved Use LOTRISONE cream contains a combination of clotrimazole, an azole antifungal, and betamethasone dipropionate, a corticosteroid, and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. Launch Date 4.58265592E11

C_max

Value	Dose	Co-administered	Analyte	Population
3.3 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7882513	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:		CLOTRIMAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
12.59 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7882513	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:		CLOTRIMAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.99 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7882513	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:		CLOTRIMAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Doses

Dose	Population	Adverse events
10 mg 5 times / day multiple, oral Recommended Dose: 10 mg, 5 times / day Route: oral Route: multiple Dose: 10 mg, 5 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2073120	unhealthy, 33 years (range: 22 - 43 years) n = 20 Health Status: unhealthy Condition: Oral Candidiasis Age Group: 33 years (range: 22 - 43 years) Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/2073120	Disc. AE: Nausea, Taste abnormality... AEs leading to discontinuation/dose reduction: Nausea (2 patients) Taste abnormality (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/2073120
500 mg single, vaginal Highest studied dose Dose: 500 mg Route: vaginal Route: single Dose: 500 mg Co-administed with:: lactic acid Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult n = 89 Health Status: unhealthy Age Group: adult Sex: F Population Size: 89 Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	Disc. AE: Vulvovaginal burning sensation... AEs leading to discontinuation/dose reduction: Vulvovaginal burning sensation (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf
500 mg single, vaginal Highest studied dose Dose: 500 mg Route: vaginal Route: single Dose: 500 mg Co-administed with:: lactic acid Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	Disc. AE: Vulvovaginal pruritus... AEs leading to discontinuation/dose reduction: Vulvovaginal pruritus (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf
50 mg 1 times / day multiple, vaginal Dose: 50 mg, 1 times / day Route: vaginal Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf Page: p. 5	unhealthy, adult n = 323 Health Status: unhealthy Age Group: adult Sex: F Population Size: 323 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf Page: p. 5	Disc. AE: Vaginal irritation, Spotting vaginal... AEs leading to discontinuation/dose reduction: Vaginal irritation (1 patient) Spotting vaginal (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf Page: p. 5

AEs

AE	Significance	Dose	Population
Nausea	2 patients Disc. AE	10 mg 5 times / day multiple, oral Recommended Dose: 10 mg, 5 times / day Route: oral Route: multiple Dose: 10 mg, 5 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2073120	unhealthy, 33 years (range: 22 - 43 years) n = 20 Health Status: unhealthy Condition: Oral Candidiasis Age Group: 33 years (range: 22 - 43 years) Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/2073120
Taste abnormality	2 patients Disc. AE	10 mg 5 times / day multiple, oral Recommended Dose: 10 mg, 5 times / day Route: oral Route: multiple Dose: 10 mg, 5 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2073120	unhealthy, 33 years (range: 22 - 43 years) n = 20 Health Status: unhealthy Condition: Oral Candidiasis Age Group: 33 years (range: 22 - 43 years) Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/2073120
Vulvovaginal burning sensation	1 patient Disc. AE	500 mg single, vaginal Highest studied dose Dose: 500 mg Route: vaginal Route: single Dose: 500 mg Co-administed with:: lactic acid Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult n = 89 Health Status: unhealthy Age Group: adult Sex: F Population Size: 89 Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf
Vulvovaginal pruritus	1 patient Disc. AE	500 mg single, vaginal Highest studied dose Dose: 500 mg Route: vaginal Route: single Dose: 500 mg Co-administed with:: lactic acid Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf
Spotting vaginal	1 patient Disc. AE	50 mg 1 times / day multiple, vaginal Dose: 50 mg, 1 times / day Route: vaginal Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf Page: p. 5	unhealthy, adult n = 323 Health Status: unhealthy Age Group: adult Sex: F Population Size: 323 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf Page: p. 5
Vaginal irritation	1 patient Disc. AE	50 mg 1 times / day multiple, vaginal Dose: 50 mg, 1 times / day Route: vaginal Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf Page: p. 5	unhealthy, adult n = 323 Health Status: unhealthy Age Group: adult Sex: F Population Size: 323 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf Page: p. 5

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A1 1 CYP3A2 10 CYP2C11 4 CYP2B1/2 3 CYP1A 72 CYP2E1 882 UGT1A1 204 UGT1A3 84 UGT1A4 77 UGT1A6 108 UGT1A9 116 UGT2B7 146 UGT2B15 64 MRP1 106		CYP1A 56 P-gp 257

Drug as perpetrator

Target	Modality	Activity
CYP2E1 970	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	no
CYP3A2 13	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	yes [IC50 0.00315 uM]
CYP3A1 5	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	yes [IC50 0.00822 uM]
CYP2B1/2 4	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	yes [IC50 0.1 uM]
CYP2C11 15	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	yes [IC50 0.745 uM]
CYP1A 121	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	yes [IC50 2.3 uM]
UGT1A1 254	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT1A3 93	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT1A4 80	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT1A6 141	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT1A9 121	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT2B15 64	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT2B7 157	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
CYP1A 121	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S0024320504008598 Page: -	yes
MRP1 172	inhibitor 3277 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1046/j.0014-2956.2001.02611.x Page: -	yes
P-gp 1650	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S1096495920301329 Page: -	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.sciencedirect.com/science/article/pii/S1056871905000523 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3764	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3764
ChemicalBook	CB7404063	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7404063
MolPort	MolPort-002-557-756	https://www.molport.com/shop/molecule-link/MolPort-002-557-756
Selleck Chemicals	Clotrimazole(Canesten)	http://www.selleckchem.com/products/Clotrimazole(Canesten).html
ZINC	ZINC000003807804	http://zinc15.docking.org/substances/ZINC000003807804
eMolecules	499093	https://www.emolecules.com/cgi-bin/more?vid=499093

PubMed

Title	Date	PubMed
Swelling-induced K(+) fluxes in vascular smooth muscle cells are mediated by charybdotoxin-sensitive K(+) channels.	2001	11832655
[Vulvovaginal candidiasis in childhood--diagnostic and therapeutic results].	2001	11799748
Topical treatment for vaginal candidiasis (thrush) in pregnancy.	2001	11687074
Tinea incognito caused by trichophyton mentagrophytes -- a case report.	2001 Dec	11879584
Effects of clotrimazole on transport mediated by multidrug resistance associated protein 1 (MRP1) in human erythrocytes and tumour cells.	2001 Dec	11737211
Regulation of K(+) current in human airway epithelial cells by exogenous and autocrine adenosine.	2001 Dec	11698258
Toward a novel metal-based chemotherapy against tropical diseases. 6. Synthesis and characterization of new copper(II) and gold(I) clotrimazole and ketoconazole complexes and evaluation of their activity against Trypanosoma cruzi.	2001 Dec 31	11754267
Outcome of 22 cases of perforated tympanic membrane caused by otomycosis.	2001 Nov	11779301
Otomycosis in Nigeria: treatment with mercurochrome.	2001 Nov	11766105
Intracellular signalling involved in activation of the volume-sensitive K+ current in Ehrlich ascites tumour cells.	2001 Oct	11913449
[How I treat ... sickle cell anemia: current therapies].	2001 Oct	11765575
Sertaconazole: in-vitro antifungal activity against vaginal and other superficial yeast isolates.	2001 Oct	11760221
In vitro activity of 6 antifungal agents on candida species isolated as causative agents from vaginal and other clinical specimens.	2001 Oct	11744942
Novel effects of minocycline on Ca(2+)-dependent Cl(-) secretion in human airway epithelial Calu-3 cells.	2001 Oct 15	11601886
Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure.	2001 Sep	11566953
Orphan nuclear receptor binding site in the human inducible nitric oxide synthase promoter mediates responsiveness to steroid and xenobiotic ligands.	2002	11891851
Interventions for treating oral candidiasis for patients with cancer receiving treatment.	2002	11869615
Clinical comparison of the efficacy and tolerability of once daily Canesten with twice daily Nizoral (clotrimazole 1% cream vs. ketoconazole 2% cream) during a 28-day topical treatment of interdigital tinea pedis.	2002 Apr	12000508
Do azoles and chloroquine share similar mechanisms of antimalarial action?	2002 Apr	11998701
Crystallization and preliminary crystallographic analysis of a novel cytochrome P450 from Mycobacterium tuberculosis.	2002 Apr	11914502
Cytochrome P450 3A conjugation to ubiquitin in a process distinct from classical ubiquitination pathway.	2002 Apr	11901229
Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy.	2002 Apr 1	11904111
Dehydration response of sickle cells to sickling-induced Ca(++) permeabilization.	2002 Apr 1	11895796
Translation initiation and its deregulation during tumorigenesis.	2002 Apr 8	11953842
Clotrimazole-triiodide ion association as an ion exchanger for a triiodide ion-selective electrode.	2002 Feb	11874113
Contribution of cytochrome P450 metabolites to bradykinin-induced vasodilation in endothelial NO synthase deficient mouse hearts.	2002 Feb	11834610
Activation of ion secretion via proteinase-activated receptor-2 in human colon.	2002 Feb	11804840
Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3.	2002 Feb 1	11826162
Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel.	2002 Feb 1	11724775
Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity.	2002 Feb 15	11830454
Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression.	2002 Feb 28	11836020
Topical antifungal drug products for over-the-counter human use; amendment of final monograph. Final rule.	2002 Feb 8	11837282
Clotrimazole binds to heme and enhances heme-dependent hemolysis: proposed antimalarial mechanism of clotrimazole.	2002 Feb 8	11707446
Comparison of two methods for antifungal susceptibility testing of Trichophyton rubrum.	2002 Jan	11913509
Development of a topical suspension containing three active ingredients.	2002 Jan	11858522
Perianal ulcerations from topical steroid use.	2002 Jan	11829184
A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy.	2002 Jan	11774397
Adenovirus vector-mediated reporter system for in vivo analyses of human CYP3A4 gene activation.	2002 Jan	11754737
Spectrofluorimetric determination of vigabatrin and gabapentin in urine and dosage forms through derivatization with fluorescamine.	2002 Jan 1	11682233
Differential pulse polarographic determination of clotrimazole after derivatization with Procion Red HE-3B.	2002 Jan 1	11682227
Topical antibiotic, antifungal, and antiseptic solutions decrease ciliary activity in nasal respiratory cells.	2002 Jan-Feb	11895191
Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections.	2002 Jan-Feb	11860579
K+ currents generated by NMDA receptor activation in rat hippocampal pyramidal neurons.	2002 Jun	12037201
The flavonol quercetin activates basolateral K(+) channels in rat distal colon epithelium.	2002 Mar	11877325
Effect of antifungal azoles on the heme detoxification system of malarial parasite.	2002 Mar	11872173
Inhibition of cytochromes P450 by antifungal imidazole derivatives.	2002 Mar	11854151
Regulation of a calcium-sensitive K+ channel (cIK1) by protein kinase C.	2002 May 1	12029379
Use of intermittent bladder infusion with clotrimazole for treatment of candiduria in a dog.	2002 May 15	12018376
Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids.	2002 May 17	12016269
Involvement of nitric oxide and potassium channels in the bradykinin-induced vasodilatation in the rat kidney perfused ex situ.	2002 May 30	11959369

Patents

Sample Use Guides

In Vivo Use Guide

Vaginal 1% cream: insert an applicator full of cream into the vagina at bedtime for 7 days. External 1% cream for vaginal yeast infections: apply to the skin outside the vagina 2 times daily for up to 7 days. Topical 1% cream: apply a thin layer to the affected area twice daily for 2 weeks (tinea pedis) or 1 week (tinea cruris and tinea corporis).

Route of Administration: Topical

In Vitro Use Guide

In vitro antifungal activity indicated Clotrimazole (MIC 16 and 8 microg/ml) effective against 68 (70%) of Candida SPP.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:05:12 UTC 2023` Edited by `admin` on `Fri Dec 15 15:05:12 UTC 2023`
Record UNII	G07GZ97H65
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLOTRIMAZOLE

Official Name

English

CLOTRIMAZOLE [GREEN BOOK]

Common Name

English

SVT-15652

Code

English

CLOTRIMAZOLE [ORANGE BOOK]

Common Name

English

GNF-PF-3499

Code

English

CLOTRIMAZOLE [USP IMPURITY]

Common Name

English

TRIVAGIZOLE

Brand Name

English

clotrimazole [INN]

Common Name

English

CLOTRIMAZOLE [MART.]

Common Name

English

CLOTRIMAZOLE [JAN]

Common Name

English

CLOTRIMAZOLE COMPONENT OF LOTRISONE

Common Name

English

Clotrimazole [WHO-DD]

Common Name

English

GYNIX

Brand Name

English

BAY-5097

Code

English

LOTRIMIN

Brand Name

English

LOTRISONE COMPONENT CLOTRIMAZOLE

Common Name

English

CLOTRIMAZOLE [MI]

Common Name

English

GYNE-LOTRIMIN

Brand Name

English

CLOTRIMAZOLE [EP IMPURITY]

Common Name

English

BAY 5097

Code

English

1-(2-CHLOROTRITYL)IMIDAZOLE

Systematic Name

English

CLOTRIMAZOLE [USP MONOGRAPH]

Common Name

English

MYCELEX

Brand Name

English

CLOTRIMAZOLE [EP MONOGRAPH]

Common Name

English

NSC-257473

Code

English

1-(O-CHLORO-.ALPHA.,.ALPHA.-DIPHENYLBENZYL)IMIDAZOLE

Common Name

English

CLOTRIMAZOLE [VANDF]

Common Name

English

1-((2-CHLOROPHENYL)DIPHENYLMETHYL)-1H-IMIDAZOLE

Systematic Name

English

CLOTRIMAZOLE [USAN]

Common Name

English

1H-IMIDAZOLE, 1-((2-CHLOROPHENYL)DIPHENYLMETHYL)-

Systematic Name

English

CLOTRIMAZOLE [USP-RS]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 524.1044G